Inactive Instrument

Analyst Reco. Acceleron Pharma Inc.

Equities

XLRN

US00434H1086

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

ACCELERON PHARMA : Jefferies Starts Acceleron Pharma at Hold With $180 Price Target	21-10-07	MT
ACCELERON PHARMA : Raymond James Downgrades Acceleron Pharma to Market Perform From Strong Buy	21-10-04	MT
ACCELERON PHARMA : Oppenheimer Suspends Rating for Acceleron Pharma, $160 Price Target on Merck Acquisition	21-10-01	MT
ACCELERON PHARMA : Morgan Stanley Downgrades Acceleron Pharma to Equalweight from Overweight, Adjusts Price Target to $180 from $150	21-10-01	MT
ACCELERON PHARMA : Barclays Downgrades Acceleron Pharma to Equal-Weight Rating From Overweight, Adjusts Price Target to $180 From $150	21-10-01	MT
ACCELERON PHARMA : Cowen Downgrades Acceleron Pharma to Market Perform from Outperform, Boosts Price Target to $180 From $173	21-10-01	MT
ANALYST RECOMMENDATIONS : Acceleron Pharma, General Mills, Southwest Airlines, Home Depot, Wizz Air...	21-10-01
ACCELERON PHARMA : HC Wainwright Downgrades Acceleron Pharma to Neutral Rating From Buy, Adjusts Price to $180 From $168	21-09-30	MT
ACCELERON PHARMA : RBC Capital Again Raises Price Target for Acceleron Pharma to $180 From $179, Maintains Sector Perform Rating	21-09-30	MT
ACCELERON PHARMA : SVB Leerink Adjusts Acceleron Pharma PT to $180 from $148, Keeps Market Perform Rating	21-09-30	MT
ACCELERON PHARMA : Piper Sandler Downgrades Acceleron Pharma to Neutral from Overweight, Adjusts PT to $180 from $146	21-09-30	MT
ACCELERON PHARMA : RBC Boosts Price Target on Acceleron Pharma to $179 From $113, Citing Deal Potential; Sector Perform Reiterated	21-09-27	MT
ACCELERON PHARMA : RBC Raises Price Target on Acceleron Pharma to $113 From $111, Reiterates Sector Perform	21-07-23	MT
ANALYST RECOMMENDATIONS : Accenture, Comcast, DoorDash, Intel, Roku...	21-06-25
ACCELERON PHARMA : Oppenheimer Adjusts Acceleron Pharma PT to $160 From $141, Maintains Outperform Rating	21-06-24	MT
ACCELERON PHARMA : Oppenheimer Adjusts Acceleron Pharma PT to $141 From $140, Maintains Outperform Rating	21-05-07	MT
ACCELERON PHARMA : SVB Leerink Downgrades Acceleron Pharma to Market Perform From Outperform, Keeps $148 Price Target	21-03-23	MT
ACCELERON PHARMA : Goldman Sachs Analyst Assumes Coverage of Acceleron Pharma With Neutral Rating, $132 Price Target	21-03-22	MT
ACCELERON PHARMA : Wolfe Research Starts Acceleron Pharma at Outperform With $200 Price Target	21-03-12	MT
ACCELERON PHARMA : Citigroup Adjusts Acceleron Pharma's Price Target to $171 from $137, Keeps Buy Rating	21-03-01	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Acceleron Pharma Inc.

Equities

XLRN

US00434H1086

Analyst Reco.

Filters